Apellis Pharmaceuticals I...

NASDAQ: APLS · Real-Time Price · USD
28.26
0.64 (2.32%)
At close: Aug 15, 2025, 10:17 AM

Apellis Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
781.37M 396.59M 75.42M 66.56M
Cost of Revenue
117.72M 58.51M 5.64M 5.2M
Gross Profit
663.64M 338.08M 69.79M 61.36M
Operating Income
-164.98M -517.12M -594.61M -536.28M
Interest Income
12.77M 20.93M 8.91M 418K
Pretax Income
-196.72M -526.5M -651.5M -746M
Net Income
-197.88M -528.63M -652.17M -746.35M
Selling & General & Admin
501.05M 500.81M 277.16M 176.77M
Research & Development
327.57M 354.39M 387.24M 420.87M
Other Expenses
n/a n/a -288K 1.36M
Operating Expenses
828.62M 855.2M 664.4M 597.64M
Interest Expense
40.39M 29.58M 32.63M 13.24M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
946.35M 913.71M 670.03M 602.84M
Income Tax Expense
1.16M 2.13M 669K 352K
Shares Outstanding (Basic)
123.91M 118.68M 106.11M 84.42M
Shares Outstanding (Diluted)
123.91M 118.68M 106.11M 84.42M
EPS (Basic)
-1.6 -4.45 -6.15 -8.84
EPS (Diluted)
-1.6 -4.45 -6.15 -8.84
EBITDA
-154.53M -495.21M -617.39M -731.27M
EBIT
-156.32M -496.92M -618.88M -732.76M
Depreciation & Amortization
1.8M 1.7M 1.49M 1.49M